Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logo The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…

More


laptop

February Final Meeting Agenda [2 pages]

Live Webcast Instructions

February 21-22, 2018

Registration Is Now Closed

Registration is NOT required to watch the live meeting webcast or to listen via telephone.


ACIP Recommendations


General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.

Guidance


ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B, for use in adults 18 years of age and older.  HEPLISAV-B is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart.  Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.

*Cytosine phosphoguanine (CpG) 1018 adjuvant

October 2017 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its October 2017 meeting:

  • The 2018 adult immunization schedule, for adults 19 years of age and older;
  • The 2018 child and adolescent immunization schedules, for children 18 years of age and younger;
  • Use of a third dose of mumps-containing vaccine for persons identified by public health as at increased risk for mumps because of an outbreak;
  • Use of Herpes Zoster subunit vaccine (Shingrix®) for the prevention of herpes zoster and its related complications for immunocompetent adults 50 years of age and older;
  • Use of Herpes Zoster subunit vaccine for immunocompetent adults who previously received Zoster Vaccine Live (Zostavax®); and
  • Preference for Herpes Zoster subunit vaccine over Zoster Vaccine Live.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.


ACIP Meetings


TOP